|
13 Companies |
|
13 Products |
|
13 Products |
|
27 Mechanisms of Action |
|
0 Trials |
|
47 News |
|
- | melphalan / Generic mfg.
Trial completion: Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). (clinicaltrials.gov) - Apr 20, 2019
P1, N=3, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Suspended --> Completed
- | Rytelo (imetelstat) / Geron
Trial termination: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Jul 20, 2018
P2, N=43, Terminated, Sponsor: Pediatric Brain Tumor Consortium
Suspended --> Completed Completed --> Terminated; Due to several intracranial hemorrhages and recommendation by the PBTC DSMB.
- || Avastin (bevacizumab) / Roche
Trial completion, Trial completion date: A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas (clinicaltrials.gov) - May 2, 2018
P1, N=27, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Completed --> Terminated; Due to several intracranial hemorrhages and recommendation by the PBTC DSMB. Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Dec 2017
- | Xalkori (crizotinib) / Pfizer
Enrollment closed: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Mar 9, 2018
P1, N=36, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Dec 2017 Recruiting --> Active, not recruiting
- | Xalkori (crizotinib) / Pfizer
Trial primary completion date: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Mar 7, 2018
P1, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2018 --> Mar 2018
- | Xalkori (crizotinib) / Pfizer
Trial primary completion date: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Aug 1, 2017
P1, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Feb 2018 --> Mar 2018 Trial primary completion date: Sep 2018 --> Dec 2017
- ||| crenolanib (ARO-002) / AROG
Trial completion: PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma (clinicaltrials.gov) - Nov 1, 2016
P1, N=55, Completed, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Sep 2018 --> Dec 2017 Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Phase classification: A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas (clinicaltrials.gov) - Aug 1, 2016
P0, N=27, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Active, not recruiting --> Completed Phase classification: P=N/A --> P0
- Avastin (bevacizumab) / Roche
Enrollment change: A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas (clinicaltrials.gov) - Jun 24, 2016
P=N/A, N=27, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Phase classification: P=N/A --> P0 N=35 --> 27
- melphalan / Generic mfg.
Trial primary completion date: Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). (clinicaltrials.gov) - May 13, 2016
P1, N=5, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=35 --> 27 Trial primary completion date: Dec 2016 --> Dec 2018
- Xalkori (crizotinib) / Pfizer
Trial primary completion date: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Apr 25, 2016
P1, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Sep 2017 --> Sep 2018
- Rytelo (imetelstat) / Geron
Trial completion: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Apr 12, 2016
P2, N=43, Completed, Sponsor: Pediatric Brain Tumor Consortium
Trial primary completion date: Sep 2017 --> Sep 2018 Active, not recruiting --> Completed
- Xalkori (crizotinib) / Pfizer
Trial primary completion date: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Feb 21, 2016
P1, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Sep 2017
- Cilcane (cilengitide) / Iceni Pharma
Trial completion, Combination therapy: CILENT-0902: Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Feb 17, 2016
P1, N=32, Completed, Sponsor: Centre Oscar Lambret
Trial primary completion date: Sep 2016 --> Sep 2017 Active, not recruiting --> Completed
- cintredekin besudotox (hIL13-PE38QQR) / Insys Therap
Trial termination: An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma (clinicaltrials.gov) - Jun 11, 2015
P1, N=7, Terminated, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- Trial completion, Trial primary completion date: Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children (clinicaltrials.gov) - Apr 21, 2015
P1/2, N=15, Completed, Sponsor: Hadassah Medical Organization
Active, not recruiting --> Terminated Recruiting --> Completed | Trial primary completion date: Feb 2020 --> Feb 2015
- melphalan / Generic mfg.
Enrollment open: Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). (clinicaltrials.gov) - Apr 16, 2015
P1, N=5, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed | Trial primary completion date: Feb 2020 --> Feb 2015 Active, not recruiting --> Recruiting
- | Caprelsa (vandetanib) / Sanofi
Trial completion: Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) (clinicaltrials.gov) - Apr 6, 2015
P1, N=25, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Xalkori (crizotinib) / Pfizer
Trial initiation date: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Mar 12, 2015
P1, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Initiation date: Nov 2012 --> Aug 2012
- melphalan / Generic mfg.
Enrollment closed: Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). (clinicaltrials.gov) - Dec 24, 2014
P1, N=5, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Initiation date: Nov 2012 --> Aug 2012 Recruiting --> Active, not recruiting
- Cilcane (cilengitide) / Iceni Pharma
Enrollment change, Combination therapy: CILENT-0902: Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Dec 12, 2014
P1, N=32, Active, not recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Active, not recruiting N=40 --> 32
- cintredekin besudotox (hIL13-PE38QQR) / Insys Therap
Enrollment closed, Enrollment change: An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma (clinicaltrials.gov) - Nov 25, 2014
P1, N=7, Active, not recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
N=40 --> 32 Recruiting --> Active, not recruiting | N=28 --> 7
- Rytelo (imetelstat) / Geron
Enrollment closed, Enrollment change: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Oct 28, 2014
P2, N=43, Active, not recruiting, Sponsor: Pediatric Brain Tumor Consortium
Recruiting --> Active, not recruiting | N=28 --> 7 Recruiting --> Active, not recruiting | N=90 --> 43
- melphalan / Generic mfg.
Trial primary completion date: Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). (clinicaltrials.gov) - Aug 26, 2014
P1, N=5, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting | N=90 --> 43 Trial primary completion date: Oct 2014 --> Dec 2016
- melphalan / Generic mfg.
Enrollment open: Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). (clinicaltrials.gov) - Jun 19, 2014
P1, N=5, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Oct 2014 --> Dec 2016 Suspended --> Recruiting
- || crenolanib (ARO-002) / AROG
Trial primary completion date: PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma (clinicaltrials.gov) - May 18, 2014
P1, N=55, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Suspended --> Recruiting Trial primary completion date: Apr 2014 --> Sep 2014
- | crenolanib (ARO-002) / AROG
Trial completion date: PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma (clinicaltrials.gov) - May 18, 2014
P1, N=55, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Apr 2014 --> Sep 2014 Trial completion date: Apr 2015 --> Sep 2015
- Cilcane (cilengitide) / Iceni Pharma
Trial termination: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents (clinicaltrials.gov) - Apr 23, 2014
P2, N=28, Terminated, Sponsor: Martin-Luther-Universit
Trial completion date: Apr 2015 --> Sep 2015 Recruiting --> Terminated; due to an altered benefit/risk assessment.
- melphalan / Generic mfg.
Trial suspension: Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). (clinicaltrials.gov) - Mar 10, 2014
P1, N=5, Suspended, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Terminated; due to an altered benefit/risk assessment. Recruiting --> Suspended
- Cilcane (cilengitide) / Iceni Pharma
Enrollment closed, Combination therapy: CILENT-0902: Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Mar 5, 2014
P1, N=40, Active, not recruiting, Sponsor: Centre Oscar Lambret
Recruiting --> Suspended Recruiting --> Active, not recruiting
- Xalkori (crizotinib) / Pfizer
Trial initiation date: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Mar 2, 2014
P1, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Initiation date: Aug 2012 --> Nov 2012
- | temozolomide / Generic mfg.
Trial completion, Surgery: Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov) - Feb 22, 2014
P2, N=170, Completed, Sponsor: Children's Oncology Group
Initiation date: Aug 2012 --> Nov 2012 Active, not recruiting --> Completed
- | Xcytrin (motexafin gadolinum) / AbbVie
Trial completion: Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma (clinicaltrials.gov) - Feb 19, 2014
P1, N=24, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- cintredekin besudotox (hIL13-PE38QQR) / Insys Therap
Enrollment change: An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma (clinicaltrials.gov) - Feb 19, 2014
P1, N=28, Recruiting, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed N=20 --> 28
- Rytelo (imetelstat) / Geron
Enrollment open: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=90, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
N=20 --> 28 Suspended --> Recruiting
- crenolanib (ARO-002) / AROG
Enrollment closed: PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma (clinicaltrials.gov) - Dec 26, 2013
P1, N=56, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Suspended --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment closed: A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas (clinicaltrials.gov) - Oct 16, 2013
P=N/A, N=35, Active, not recruiting, Sponsor: Children's Hospital Medical Center, Cincinnati
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Enrollment open: Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children (clinicaltrials.gov) - Jul 7, 2013
P1/2, N=15, Recruiting, Sponsor: Hadassah Medical Organization
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Rytelo (imetelstat) / Geron
New P2 trial: Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors (clinicaltrials.gov) - Apr 18, 2013
P2, N=90, Recruiting, Sponsor: Pediatric Brain Tumor Consortium
- || TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon
Trial completion: Nimotuzumab in Children With Intrinsic Pontine Glioma (clinicaltrials.gov) - Mar 26, 2013
P3, N=41, Completed, Sponsor: Oncoscience AG
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P1/2 trial: Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children (clinicaltrials.gov) - Jan 27, 2013
P1/2, N=15, Recruiting, Sponsor: Hadassah Medical Organization
- melphalan / Generic mfg.
New P1 trial: Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). (clinicaltrials.gov) - Sep 17, 2012
P1, N=5, Suspended, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- Xalkori (crizotinib) / Pfizer
Enrollment open: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Aug 30, 2012
P1, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Xalkori (crizotinib) / Pfizer
New P1 trial: Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) (clinicaltrials.gov) - Jul 17, 2012
P1, N=50, Recruiting, Sponsor: St. Jude Children's Research Hospital
- Cilcane (cilengitide) / Iceni Pharma
New P2 trial: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents (clinicaltrials.gov) - Jan 23, 2012
P2, N=28, Terminated, Sponsor: Martin-Luther-Universit
- ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas (clinicaltrials.gov) - Jan 9, 2012
P2, N=32, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed